Efalex Improves Social Responses and Attention in Children and Adolescents with Autism
Objective: To determine the efficacy and safety of Efalex to reduce symptoms of autism and to determine the relationship between blood fatty acid status and treatment response. Assessments: Conclusion: Efalex can safely and effectively reduce autism symptoms Relevance to: Efalex Brain Formula
Efamol GAIT PR Coverage
Efamol GAIT PR Coverage: STUDY SUGGESTS SUPPLEMENTATION PRODUCES SIMILAR EFFECTS ON BRAIN FUNCTION TO EXERCISE A new study, published in The British Journal of Nutrition suggests that daily supplementation with an omega-3 fatty acid fish oil containing 1000mg of DHA plus supporting nutrients produces similar improvements in brain function to exercise in older women. The […]
Effects of Treatment on Cognition and Mobility
Effects of Treatment on Cognition and Mobility: Click here to view PDF Background and Objective: A complex relationship exists between mobility and cognition with studies demonstrating how in older people a decline in gait performance often precedes or coexists with a decline in cognition. Consequently this study aimed to determine whether a DHA rich multi- […]
Omega-3 intake prevents age-related macular degeneration
Omega-3 intake prevents age-related macular degeneration: The latest review of the science linking omega-3 intake to lower incidence of age-related macular degeneration (AMD) has concluded that the potential therapeutic benefit of omega-3 fatty acid supplementation is supported by the role of these fatty acids in normal retinal physiology, their anti-inflammatory properties, and the putative role […]
Health benefits from fish intake may be attributed to a combination of selenium and omega-3 fatty acids
A recent study has looked at the relationship between omega-3 fatty acids and selenium intake relative to health benefits form fish in the elderly. This study, supported by a grant from the French Alzheimer’s disease association was carried out under agreement between the Merck, Sharp and Dohme-Chibret Laboratories and EISAI laboratory, France. It provided […]
Fish oil fatty acids and anti-oxidant nutrients reduce risk of age-related macular degeneration in people with a genetic susceptibility
Age-related macular degeneration A new study found that among people with a genetic susceptibility to age-related macular degeneration (AMD), those who ate more zinc, beta-carotene, lutein/zeaxanthin and the omega-3 eicospaentaenoic acid (EPA) and docosahexaenoic acid (DHA) cut their risk of developing the condition by up to a third compared with those who ate less of […]
High dietary intake of EPA/DHA, zinc, beta-carotene and lutein/zeaxanthin reduces the risk of early AMD in people with high genetic risk of developing the condition
Topics: Omega-3 fatty acids, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), long chain polyunsaturated fatty acids (LC-PUFAs), age-related macular degeneration (AMD), zinc, anti-oxidants, Vitamins A, C & E, beta-carotene, lutein/zeaxanthin. Objective: To investigate whether omega-3 fatty acids, zinc, Vitamins A, C & E, beta-carotene and lutein/zeaxanthin can reduce the genetic risk of early AMD conferred by […]
New study shows Omega-3 reduce admission to hospital and deaths from heart failure
Omega-3 : The first large scale clinical trial assessing the effects of Omega-3 fatty acids on risk reduction in cardiac patients has measured significant benefits. The study, dubbed the GISSI-HF Trial (Gruppo Italiano per lo Studio della Soprevvivenza nell’Infarto miocardico) included 6975 patients from 326 cardiology and 31 internal medicine centres in Italy. All had […]
Questions on Fish Oil, Sustainability and the Environment
Fish Oil, Sustainability and the Environment Q. What is your position on global overfishing? A. Global overfishing is a major concern that is currently being taken very seriously by countries around the world. Boris Worm from Dalhousie University, Halifax, Nova Scotia, brought the issue to a head in Nov 2006 when he and 13 other scientists […]
The Ultimate Efamol Trial
The trial included 40 healthy males and females between the ages of 32 and 56 years that were randomly assigned to take either six 500 mg capsules per day of Efamol® EPO or an inert placebo for 84 days. Each group of patients was roughly comprised of an equal number of males and females. During […]